Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

BACKGROUND: Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluated changes in laboratory parameters and immunopharmacodynamic markers in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Nägele, Virginie, Kratzer, Andrea, Zugmaier, Gerhard, Holland, Chris, Hijazi, Youssef, Topp, Max S., Gökbuget, Nicola, Baeuerle, Patrick A., Kufer, Peter, Wolf, Andreas, Klinger, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437652/
https://www.ncbi.nlm.nih.gov/pubmed/28533941
http://dx.doi.org/10.1186/s40164-017-0074-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437652/
https://www.ncbi.nlm.nih.gov/pubmed/28533941
http://dx.doi.org/10.1186/s40164-017-0074-5

Ejemplares similares